Company

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
BiosimilarsBoan Biotechnology

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that it has entered into a collaboration agreement with a partner for the Japan rights to its denosumab injection 60 mg (BA6101),…

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Aidea Pharma's Aitribond Approved by Zanzibar Food and Drug Agency
Aidea PharmaceuticalProduct approvals

Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan
CancerHKG: 2629

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30
Ascletis PharmaClinical trial approval / initiation

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Sobi North America's Doptelet Approved by FDA for Pediatric ITP Treatment
Pediatric drugsProduct approvals

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Show More